Donanemab — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for Alzheimer’s disease.
Donanemab has been evaluated under the MARA Rating framework for its role in slowing cognitive decline in early Alzheimer’s disease. The overall MARA Score is B++ (Marginal), with a numeric value of 2.3 out of 4. This result falls below the 5-year therapeutic-area average in neurology (2.9) and the broader industry 5-year average (3.0), indicating relatively weaker market-access prospects.
Clinical Effectiveness: Statistically Significant but Limited Long-Term Data
Donanemab demonstrated a statistically significant benefit over placebo, showing a 22% slowing of decline on the iADRS score. The treatment achieved both primary and secondary endpoints, confirming short-term efficacy. However, uncertainty remains due to limited long-term follow-up data, leaving questions about durability of effect.
Comparator Selection: Highest Rating
The use of placebo alongside standard care accurately represented real-world practice and adhered to prevailing clinical guidelines, ensuring that the trial findings are directly relevant to current treatment contexts.
Care-Pathway Integration: Weak Rating
Successful use of donanemab requires extensive diagnostic and monitoring infrastructure, including amyloid PET scans and regular MRIs. These requirements add significant complexity to its adoption and may pose challenges for health systems, even though implementation remains possible with adequate planning and resources.
About MARA Rating®
The MARA Rating synthesizes ten dimensions of market access risk—clinical efficacy, health-economic value, safety profile, comparator robustness, budget impact, and more—each scored on a seven-level scale (A++ to C). We then apply evidence-based weightings to generate a single risk score. A high MARA Score (A to A++) signals strong access prospects; a low score (B++ to C) denotes elevated pricing and potential reimbursement hurdles.
Unlock Premium Insights
Explore seven additional domains: Quality of Life (HRQoL), Cost-Effectiveness, Safety, Patient Population, Resource Use & Cost Implications, Evidence Quality, and Uncertainty. Available exclusively in Premium Insights at mararating.com.
Full Premium Report available upon request: Visit mararating.com or send us an email at: sales@mararating.com to learn more and unlock your access.
Disclaimer: The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only – not as investment, medical, legal or any other type of advice. See our full disclaimer in mararating.com
Access this report and hundreds of others here: https://mararating.com/mara-ratings-list.